Company Encyclopedia
View More
name
Cannabis
CP00006.US
News
View More

Teva seeks startups to help solve global pharmaceutical challenges

Teva Pharmaceutical Industries has launched Teva Rise, an open innovation platform inviting startups to develop technologies addressing challenges in R&D, manufacturing, supply chain, and commercial sectors. The initiative aims to leverage AI, digital health, and smart manufacturing to improve drug development and patient care. Teva plans to invest tens of millions of dollars in global partnerships with startups to enhance its business and deliver value to patients.

Reuters·
US
TEVA
+1.02%
Reuters·
US
TEVA
+1.02%

Teva Pharmaceutical Industries Ltd. $TEVA is Clal Insurance Enterprises Holdings Ltd's 4th Largest Position

Clal Insurance reduced its stake in Teva Pharmaceutical by 14.5% in Q2, owning 32.36M shares worth $543M. Teva's stock is Clal's 4th largest position. Other investors adjusted their holdings, with hedge funds owning 54.05% of Teva's stock. Teva's Q3 earnings beat estimates, reporting $0.78 EPS and $4.48B revenue. Analysts raised price targets, with JPMorgan setting $28.00. Insider Roberto Mignone sold 200,000 shares. Teva's stock opened at $24.86, with a market cap of $28.51B.

Market Beat·
US
TEVA
+1.02%
Market Beat·
US
TEVA
+1.02%

Teva EVP Head of U.S. Commercial Christine Fox Reports Disposal of Common Shares

Christine Fox, EVP, Head of U.S. Commercial at Teva Pharmaceutical Industries Ltd., reported the disposal of common shares of the company. The filing is available via EDGAR, the SEC's system.

Reuters·
US
TEVA
+1.02%
Reuters·
US
TEVA
+1.02%

Canopy Growth Launches New Spectrum Therapeutics Softgels in Australia

Canopy Growth Corporation has expanded its Spectrum Therapeutics portfolio in Australia by launching new softgel capsules for medical cannabis patients. The new products include Spectrum Yellow, Red, and Blue Cannabis Oil Softgels, offering various CBD and THC combinations. This expansion aims to provide more choices for patients and prescribers, reinforcing Canopy Growth's commitment to its international medical cannabis business. The softgels are available through authorized prescribers in Australia.

Reuters·
US
CGC
+1.90%
Reuters·
US
CGC
+1.90%

Cronos Group Inc. Stock Falls Monday, Underperforms Market

Shares of Cronos Group Inc. (CRON) fell 1.22% to $2.42 on Monday, underperforming the market. The NASDAQ Composite Index fell 0.84% and the Dow Jones Industrial Average fell 1.18%. This marks the third consecutive day of losses for Cronos Group Inc., which is 23.42% below its 52-week high of $3.16. Trading volume was 970,258, below the 50-day average of 2.1 million.

Dow Jones·
US
CRON
+0.83%
Dow Jones·
US
CRON
+0.83%